Clinical trials: in Austria
Pancreatic Cancer, Advanced Pancreatic Carcinoma
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in Austria
- Trial name
- ADPACA (NCT05526443)
- Testing
- all approved chemotherapeutic agents from second line
- Where
- 14 sites in Austria
- Volunteers
- 1,500 people
- Sponsor
- Medical University of Graz
Locally Advanced Carcinoma, Metastatic Cancer
Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) From Liquid and/or Tissue Biopsy in Patients With Locally Advanced and/or Metastatic Solid Cancer
The aims of this study are to evaluate the efficacy of comprehensive genomic tumour profiling (CGP) from liquid and/or tissue biopsy in patients with locally advanced and/or metastatic solid cancer.
- Trial name
- SOUND (NCT05032092)
- Testing
- Next Generation Sequencing, Biomarker Monitoring
- Where
- 6 sites in Austria
- Volunteers
- 235 people
- Sponsor
- Medical University of Graz
Intracranial Hemorrhages, Atrial Fibrillation
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and…
- Trial name
- ENRICH-AF (NCT03950076)
- Testing
- Edoxaban, Non-anticoagulant medical therapy
- Where
- 152 sites in United States, Argentina and 13 more
- Volunteers
- 948 people
- Sponsor
- Population Health Research Institute
Hereditary Spastic Paraplegia, Spastic Ataxia
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias
Ataxias, hereditary spastic paraplegias (HSP), and spastic ataxias (collectively referred to as SPAX diseases) are rare neurological conditions that cause progressive problems with walking, balance, coordination, and daily…
- Trial name
- TreatHSP (NCT07798674)
- Where
- 30 sites in Austria, Czechia and 7 more
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Friedreich Ataxia
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological…
- Trial name
- UNIFAI (NCT06016946)
- Where
- 34 sites in United States, Australia and 15 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Friedreich's Ataxia Research Alliance
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study…
- Trial name
- LTSAFE-ALXN (NCT07789483)
- Testing
- ALXN2220
- Where
- 195 sites in United States, Argentina and 25 more
- Volunteers
- 1,180 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP.
- Trial name
- NCT04971226
- Testing
- Imatinib, Nilotinib, Bosutinib
- Where
- 110 sites in United States, Australia and 27 more
- Volunteers
- 405 people
- Sponsor
- Novartis Pharmaceuticals
Highly Sensitized Patients Awaiting Kidney Transplant
OM336 in Sensitized Transplant Candidates
This investigator-initiated, single-arm, open-label Phase IIa pilot study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OM336 in highly HLA-sensitized adults with chronic…
- Trial name
- NCT07789431
- Testing
- OM3436
- Where
- 2 sites in Austria, Germany
- Volunteers
- 12 people
- Sponsor
- Medical University of Vienna
Inherited Retinal Diseases
Global Patient Registry of Inherited Retinal Diseases
The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.
- Trial name
- EYERD Registry (NCT05957276)
- Testing
- Standard of Care
- Where
- 75 sites in United States, Australia and 16 more
- Volunteers
- 886 people
- Sponsor
- Janssen Research & Development, LLC
Cervical Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the…
- Trial name
- NCT06459180
- Testing
- Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 686 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Disease and Lipoprotein(a)
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
- Trial name
- Lp(a)HORIZON (NCT04023552)
- Testing
- TQJ230
- Where
- 902 sites in United States, Argentina and 41 more
- Volunteers
- 8,323 people
- Sponsor
- Novartis Pharmaceuticals
Persistent Atrial Fibrillation
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial…
- Trial name
- AVANT GUARD (NCT06096337)
- Testing
- FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
- Where
- 61 sites in United States, Australia and 11 more
- Volunteers
- 484 people
- Sponsor
- Boston Scientific Corporation
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy.
- Trial name
- TroFuse-005 (NCT06132958)
- Testing
- Sacituzumab tirumotecan, Doxorubicin, Paclitaxel
- Where
- 242 sites in United States, Argentina and 29 more
- Volunteers
- 710 people
- Sponsor
- Merck Sharp & Dohme LLC
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.
- Conditions
- Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
- Trial name
- NCT05338970
- Testing
- Patritumab Deruxtecan, Platinum-based chemotherapy
- Where
- 182 sites in United States, Australia and 19 more
- Volunteers
- 586 people
- Sponsor
- Daiichi Sankyo
Multiple Myeloma
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- CERVINO (NCT06158841)
- Testing
- Etentamig, Carfilzomib, Pomalidomide
- Where
- 166 sites in United States, Australia and 23 more
- Volunteers
- 421 people
- Sponsor
- AbbVie
Essential Thrombocythemia
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated.
- Trial name
- NCT06456346
- Testing
- Bomedemstat, Hydroxyurea
- Where
- 171 sites in United States, Argentina and 21 more
- Volunteers
- 300 people
- Sponsor
- Merck Sharp & Dohme LLC
Treatment Resistant Depression
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve…
- Trial name
- RESTORE-LIFE (NCT03320304)
- Testing
- Vagal Nerve Simulation (VNS) Therapy
- Where
- 18 sites in Austria, Belgium and 2 more
- Volunteers
- 500 people
- Sponsor
- LivaNova
Carcinoma, Non-Small-Cell Lung
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Using a laboratory test (VeriStrat), patients with relapsed squamous cell lung cancer are assigned to two strata, VSG (VeriStrat Good) and VSP (VeriStrat Poor).
- Trial name
- EMPHASIS (NCT01652469)
- Testing
- Erlotinib, Docetaxel
- Where
- 32 sites in Austria, Belgium and 10 more
- Volunteers
- 81 people
- Sponsor
- ETOP IBCSG Partners Foundation
Geographic Atrophy
A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD).
- Trial name
- Proxima A (NCT02479386)
- Testing
- No intervention
- Where
- 91 sites in United States, Argentina and 13 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Melanoma
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in…
- Trial name
- RELATIVITY-127 (NCT05625399)
- Testing
- Nivolumab + Relatlimab, rHuPH20
- Where
- 149 sites in United States, Australia and 17 more
- Volunteers
- 579 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.